Chinese cancer drug ivonescimab reduces mortality by 34 percent

The drug ivonescimab from Akeso and its partner Summit Therapeutics reduces the risk of death in previously untreated Chinese lung cancer patients by 34 percent compared to standard therapy combining immunotherapy and chemotherapy. Bloomberg reports on the results presented at the annual conference of the American Society of Clinical Oncology (ASCO26) in Chicago.

The study focused on patients with squamous cell carcinoma of the lung, a particularly aggressive form of lung cancer. STAT documents that patients receiving ivonescimab achieved a survival extension of four months compared to the control group. This is a clinically relevant difference that underscores the effectiveness of the approach.

New immunotherapy in competition

Ivonescimab belongs to a new generation of immunotherapies that exploit multiple points of attack in the body. CNBC reports that the drug competes in an intense race for the most effective lung cancer therapy. The positive data could give Akeso an advantage in the global market, especially if the results are confirmed in Western patient populations.

The results represent a breakthrough for the Chinese biotech company: they suggest that ivonescimab is not only effective but may exceed existing standards. Endpoints News adds that such survival data are central to the approval of new cancer drugs and can influence regulatory authorities worldwide.

Akeso now plans to advance approval processes in various markets. Whether the results can be reproduced outside China remains an open question for the coming months.